Cargando…

Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program

Background and Aim: Data on the clinical pharmacokinetics of cannabidiol (CBD) are scanty. We explored the effect of demographic and clinical variables on plasma concentrations of purified CBD in patients with Dravet (DS) and Lennox–Gastaut syndrome (LGS). Methods: The study design was an open, pros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Contin, Manuela, Mohamed, Susan, Santucci, Margherita, Lodi, Monica Anna Maria, Russo, Emilio, Mecarelli, Oriano, CBD LICE Italy Study Group
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966506/ https://www.ncbi.nlm.nih.gov/pubmed/33746760 http://dx.doi.org/10.3389/fphar.2021.637801

Ejemplares similares

Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox–Gastaut Syndrome
por: Iannone, Luigi Francesco, et al.
Publicado: (2021)

Cortical stimulation in pharmacoresistant focal epilepsies
por: Ellrich, Jens
Publicado: (2020)

Genetic variations associated with pharmacoresistant epilepsy
por: Cárdenas-Rodríguez, Noemí, et al.
Publicado: (2020)

Vagal nerve stimulation for pharmacoresistant epilepsy in children
por: Hauptman, Jason S., et al.
Publicado: (2012)

Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine
por: Dini, Gianluca, et al.
Publicado: (2022)

Pharmacoresistant Abdominal Seizures in Symptomatic Localization-Related Epilepsy
por: Tushar, Vadakke Puthanveetil, et al.
Publicado: (2021)

The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies
por: Fattorusso, Antonella, et al.
Publicado: (2021)

Transporter hypothesis in pharmacoresistant epilepsies. Is it at the central or peripheral level?
por: Czornyj, Liliana, et al.
Publicado: (2021)

Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine
por: Dini, Gianluca, et al.
Publicado: (2023)

Effect of Oxidative Stress on ABC Transporters: Contribution to Epilepsy Pharmacoresistance
por: Grewal, Gurpreet Kaur, et al.
Publicado: (2017)

A complex systems view on the current hypotheses of epilepsy pharmacoresistance
por: Servilha‐Menezes, Gabriel, et al.
Publicado: (2022)

Functional Connectivity Derived From Electroencephalogram in Pharmacoresistant Epileptic Encephalopathy Using Cannabidiol as Adjunctive Antiepileptic Therapy
por: Morales Chacón, Lilia Maria, et al.
Publicado: (2021)

The 50th anniversary of the Italian League against epilepsy (Lega Italiana Contro l’Epilessia)()
por: Tassi, Laura, et al.
Publicado: (2022)

Lower fat and better quality diet therapy for children with pharmacoresistant epilepsy
por: Yoon, Jung-Rim, et al.
Publicado: (2013)

7T MRI with post-processing for the presurgical evaluation of pharmacoresistant focal epilepsy
por: Chen, Cong, et al.
Publicado: (2021)

‘Hippocampal innate inflammatory gliosis only’ in pharmacoresistant temporal lobe epilepsy
por: Grote, Alexander, et al.
Publicado: (2022)

Limbic network co‐localization predicts pharmacoresistance in dysplasia‐related epilepsy
por: Cohen, Nathan T., et al.
Publicado: (2023)

Assessing knowledge and attitudes toward epilepsy among schoolteachers and students: Implications for inclusion and safety in the educational system
por: Iannone, Luigi Francesco, et al.
Publicado: (2021)

Effects of Surgical Side and Site on Mood and Behavior Outcome in Children with Pharmacoresistant Epilepsy
por: Andresen, Elizabeth N., et al.
Publicado: (2014)

Pharmacoresistant Epilepsy in Childhood: Think of the Cerebral Folate Deficiency, a Treatable Disease
por: Mafi, Sarah, et al.
Publicado: (2020)

Gephyrin and CYP2C9 Genetic Polymorphisms in Patients with Pharmacoresistant Epilepsy
por: El-Tallawy, Hamdy N, et al.
Publicado: (2021)

Network Substrates of Centromedian Nucleus Deep Brain Stimulation in Generalized Pharmacoresistant Epilepsy
por: Torres Diaz, Cristina V., et al.
Publicado: (2021)

Multi‐omic strategies applied to the study of pharmacoresistance in mesial temporal lobe epilepsy
por: Bruxel, Estela M., et al.
Publicado: (2021)

Pharmacoresistant Epilepsy: A Current Update on Non-Conventional Pharmacological and Non-Pharmacological Interventions
por: Sharma, Arun Kumar, et al.
Publicado: (2015)

Bilateral stereotactic lesions and chronic stimulation of the anterior thalamic nuclei for treatment of pharmacoresistant epilepsy
por: Sitnikov, A. R., et al.
Publicado: (2018)

Altered structural connectome in non-lesional newly diagnosed focal epilepsy: Relation to pharmacoresistance
por: Kreilkamp, Barbara A.K., et al.
Publicado: (2021)

Cannabidiol in the Treatment of Epilepsy
por: von Wrede, Randi, et al.
Publicado: (2021)

Clinical and Electroencephalography Assessment of the Effects of Brivaracetam in the Treatment of Drug-Resistant Focal Epilepsy
por: Savastano, Ersilia, et al.
Publicado: (2021)

A Clinical-EEG Study of Sleepiness and Psychological Symptoms in Pharmacoresistant Epilepsy Patients Treated with Lacosamide
por: Giorgi, Filippo S., et al.
Publicado: (2013)

Role of DNA Methylation and Adenosine in Ketogenic Diet for Pharmacoresistant Epilepsy: Focus on Epileptogenesis and Associated Comorbidities
por: Chen, Fan, et al.
Publicado: (2019)

Radiological and Clinical Value of 7T MRI for Evaluating 3T-Visible Lesions in Pharmacoresistant Focal Epilepsies
por: Wang, Z. Irene, et al.
Publicado: (2021)

Reduction in anti-seizure medications use in pediatric patients with pharmacoresistant epilepsy submitted to surgical treatment
por: de Matos, Maiave Micaelle Figueiredo, et al.
Publicado: (2022)

Vagus nerve stimulation for pharmacoresistant epilepsy secondary to encephalomalacia: A single-center retrospective study
por: Guo, Mengyi, et al.
Publicado: (2023)

Brain functional connectivity‐based prediction of vagus nerve stimulation efficacy in pediatric pharmacoresistant epilepsy
por: Chen, Hao, et al.
Publicado: (2023)

FALSE PHARMACORESISTANCE – A TRUE PROBLEM
por: Bašić, Silvio, et al.
Publicado: (2021)

Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results
por: Szaflarski, Jerzy P., et al.
Publicado: (2018)

Cannabidiol as a treatment for epilepsy
por: Pickrell, William O., et al.
Publicado: (2017)

Cannabidiol in epilepsy: The indications and beyond
por: Ryan, Melody
Publicado: (2020)

Endocannabinoid System and Cannabinoid 1 Receptors in Patients With Pharmacoresistant Temporal Lobe Epilepsy and Comorbid Mood Disorders
por: Rocha, Luisa, et al.
Publicado: (2020)

Chaotic and stochastic dynamics of epileptiform-like activities in sclerotic hippocampus resected from patients with pharmacoresistant epilepsy
por: Araújo, Noemi S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uug2o9g16062rkfcak300a1enr